Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | DHODH | Q02127 | 3/20 | 0.58 |
| ▸ | MASP2 | O00187 | 1/20 | 0.58 |
| ▸ | CFD | P00746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11727177 | 0.94 | DHODH (0.67) | KMT2AMAPTCTSKMEN1PKM | |
| SCHEMBL4075771 | 0.86 | KMT2A (0.53) | KMT2AMAPTCTSKMEN1PKM | |
| SCHEMBL7974580 | 0.86 | KMT2A (0.57) | KMT2AMAPTCTSKMEN1PKM | |
| Benzene SCHEMBL27690342 | 0.86 | KMT2A (0.57) | KMT2AMAPTCTSKMEN1PKM | |
| SCHEMBL233797 | 0.86 | KMT2A (0.57) | KMT2AMAPTCTSKMEN1PKM | |
| SCHEMBL3627546 | 0.86 | MASP2 (0.62) | KMT2AMAPTCTSKMEN1PKM | |
| SCHEMBL13936398 | 0.84 | DHODH (0.64) | KMT2AMAPTCTSKMEN1PKM | |
| SCHEMBL4749159 | 0.84 | DHODH (0.69) | KMT2AMAPTMEN1PKMDHODH | |
| SCHEMBL5365142 | 0.84 | KDM4E (0.65) | KMT2AMAPTMEN1PKMALDH1A1 | |
| SCHEMBL211260 | 0.84 | KMT2A (0.61) | KMT2AMEN1PKMDHODHMASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123274-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2001-08-16 | — | — | EP | claimed |
| WO-2000024707-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-05-04 | — | — | WO | claimed |
| US-4996339-A | Colorless | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-26 | — | — | US | claimed |
| US-4855208-A | Toner for developing electrostatic latent images | ORIENT CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-08 | — | — | US | claimed |
| JP-10251237-A | — | — | None | — | — | JP | disclosed |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688756-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206345-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-4370111-A1 | DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTS | Universität Hamburg (DE) | 2024-05-22 | — | — | EP | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-4657893-A | ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0147211-A2 | 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4421931-A | Preparation of anthranilic acid amides | BASF AKTIENGESELLSCHAFT (DE) | 1983-12-20 | — | — | US | disclosed |
| US-4362876-A | Preparation of dihydroxyquinoline and certain derivatives | THE SHERWIN-WILLIAMS COMPANY (US) | 1982-12-07 | — | — | US | disclosed |
| EP-0057424-A1 | Process for the preparation of anthranilic acid amides | BASF Aktiengesellschaft (DE) | 1982-08-11 | — | — | EP | disclosed |
| US-4177041-A | FUEL ADDITIVES | TEXACO INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4154755-A | Manufacture of N-(2-cyanophenyl)-formamidines | BASF AKTIENGESELLSCHAFT (DE) | 1979-05-15 | — | — | US | disclosed |
| US-3991015-A | High molecular weight copolyamides containing quinazoline dione units | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MAPT 2761/4885CTSK 2647/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | KMT2A 1817/4885MAPT 2761/4885CTSK 2647/4885 |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | KMT2A 4427/4885MAPT 2768/4885CTSK 1431/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | KMT2A 4584/4885MAPT 4191/4885CTSK 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.